TY - JOUR
T1 - A 10-year study reveals clinical and laboratory evidence for the ‘semi-invasive’ properties of chronic pulmonary aspergillosis
AU - Chan, Jasper Fuk Woo
AU - Lau, Susanna Kar Pui
AU - Wong, Sally Cheuk Ying
AU - To, Kelvin Kai Wang
AU - So, Simon Yung Chun
AU - Leung, Sally Sau Man
AU - Chan, Siu Mang
AU - Pang, Chiu Mei
AU - Xiao, Chenlu
AU - Hung, Ivan Fan Ngai
AU - Cheng, Vincent Chi Chung
AU - Yuen, Kwok Yung
AU - Woo, Patrick Chiu Yat
N1 - Publisher Copyright:
© 2016 The Author(s).
PY - 2016
Y1 - 2016
N2 - In recent years, infections caused by Aspergillus sp. have become an emerging focus of clinical microbiology and infectious disease, as the number of patients infected with Aspergillus sp. has increased markedly. Although chronic pulmonary aspergillosis (CPA) is considered a ‘semi-invasive’ or ‘intermediate’ disease, little data are available for the direct comparison of CPA with invasive pulmonary aspergillosis (IPA) and pulmonary aspergilloma (PA) to quantify invasiveness. In this study, we compared the characteristics of CPA with those of IPA and PA among hospitalized patients over a 10-year period. A total of 29, 51 and 31 cases of CPA, IPA and PA, respectively, were included. An increasing trend in galactomannan antigen seropositivity rate from PA (24.1%) to CPA (35.7%) to IPA (54.9%) and an opposite trend for anti-Aspergillus antibody (PA (71.0%) to CPA (45.8%) to IPA (7.1%)) were observed. Eight percent of CPA patients were infected with more than one Aspergillus sp. The survival rate of the CPA group also fell between the survival rate of PA and IPA, confirming the intermediate severity of CPA. The survival rate of the CPA group became significantly higher than that of the IPA group from day 180 onwards until 2 years after admission (P<0.05). The survival rate of the CPA group remained lower than that of the PA group from day 30 onwards until 2 years after admission. Poor prognostic factors for CPA included older age (P=0.019), higher total leukocyte count (P=0.011) and higher neutrophil count (P=0.012) on admission. This study provided clinical and laboratory evidence for the semi-invasive properties of CPA. Emerging Microbes and Infections (2016) 5, e37; doi:10.1038/emi.2016.31; published online 20 April 2016.
AB - In recent years, infections caused by Aspergillus sp. have become an emerging focus of clinical microbiology and infectious disease, as the number of patients infected with Aspergillus sp. has increased markedly. Although chronic pulmonary aspergillosis (CPA) is considered a ‘semi-invasive’ or ‘intermediate’ disease, little data are available for the direct comparison of CPA with invasive pulmonary aspergillosis (IPA) and pulmonary aspergilloma (PA) to quantify invasiveness. In this study, we compared the characteristics of CPA with those of IPA and PA among hospitalized patients over a 10-year period. A total of 29, 51 and 31 cases of CPA, IPA and PA, respectively, were included. An increasing trend in galactomannan antigen seropositivity rate from PA (24.1%) to CPA (35.7%) to IPA (54.9%) and an opposite trend for anti-Aspergillus antibody (PA (71.0%) to CPA (45.8%) to IPA (7.1%)) were observed. Eight percent of CPA patients were infected with more than one Aspergillus sp. The survival rate of the CPA group also fell between the survival rate of PA and IPA, confirming the intermediate severity of CPA. The survival rate of the CPA group became significantly higher than that of the IPA group from day 180 onwards until 2 years after admission (P<0.05). The survival rate of the CPA group remained lower than that of the PA group from day 30 onwards until 2 years after admission. Poor prognostic factors for CPA included older age (P=0.019), higher total leukocyte count (P=0.011) and higher neutrophil count (P=0.012) on admission. This study provided clinical and laboratory evidence for the semi-invasive properties of CPA. Emerging Microbes and Infections (2016) 5, e37; doi:10.1038/emi.2016.31; published online 20 April 2016.
KW - aspergilloma
KW - aspergillosis
KW - chronic
KW - invasive
KW - pulmonary
UR - http://www.scopus.com/inward/record.url?scp=85015921481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015921481&partnerID=8YFLogxK
U2 - 10.1038/emi.2016.31
DO - 10.1038/emi.2016.31
M3 - Article
C2 - 27094904
AN - SCOPUS:85015921481
SN - 2222-1751
VL - 5
SP - 1
EP - 7
JO - Emerging Microbes and Infections
JF - Emerging Microbes and Infections
IS - 1
ER -